HLA-A and synovial sarcoma: Based on the results of the open-label Phase 2 study SPEARHEAD-1,10 the Food and Drug Administration (FDA) has granted accelerated approval to afamitresgene autoleucel (TECELRA, Adaptimmune, LLC), or afami-cel, for adults with advanced SS who have received prior chemotherapy and have specific human leukocyte antigen (HLA) allele (HLA-A*02:01, 02:02, 02:03, or 02:06), absence of a homozygous or heterozygous HLA-A*02:05 allele, and whose tumors express MAGE-A4 antigen.13